Ningxia 2010 biomedical exports will complete 50 million US dollars

In the face of the financial crisis, foreign customers of Ningxia biopharmaceutical companies not only did not reduce, but also added markets such as India, Thailand and Brazil. In 2009, the Ningxia Hui Autonomous Region biopharmaceutical companies increased technological innovation and explored the international market. The biomedical exports amounted to US$101.78 million, exceeded US$100 million for the first time, an increase of 5.2% over the previous year, and the number of fist export products reached more than four.

Ningxia Qiyuan Pharmaceutical timely adjusted its product structure and marketing strategy, deepened technological innovation and transformation, increased overseas participation and market visits, strengthened communication with important markets and customers, and established a stable customer base and marketing network.

In 2009, the company actually achieved a foreign exchange earning of USD 64.62 million with an index completion rate of 108%. Its product, erythromycin, is in short supply, and its product market share and profitability for operating companies are far ahead in the industry.

Ningxia Duowei Tairui Pharmaceutical Co., Ltd. took the initiative to communicate with customers and dispel the worries of major foreign customers. Last year, the company’s export sales amounted to US$40.3 million, an increase of 20.7% over the previous year.

At present, the company has a contract of 3 million U.S. dollars and is expected to complete 50 million U.S. dollars in exports this year.